Capstone Investment Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,400
| Closed | -$774K | – | 1597 |
|
|
2025
Q4 | $774K | Sell |
4,400
-300
| -6% | -$49K | ﹤0.01% | 974 |
|
|
2025
Q3 | $658K | Buy |
4,700
+1,600
| +52% | +$216K | ﹤0.01% | 1219 |
|
|
2025
Q2 | $389K | Sell |
3,100
-700
| -18% | -$87.2K | ﹤0.01% | 1263 |
|
|
2025
Q1 | $520K | Sell |
3,800
-20,000
| -84% | -$2.86M | ﹤0.01% | 1067 |
|
|
2024
Q4 | $3.64M | Buy |
23,800
+16,400
| +222% | +$2.77M | 0.01% | 650 |
|
|
2024
Q3 | $1.43M | Buy |
7,400
+900
| +14% | +$188K | ﹤0.01% | 843 |
|
|
2024
Q2 | $1.51M | Buy |
6,500
+2,600
| +67% | +$565K | ﹤0.01% | 831 |
|
|
2024
Q1 | $841K | Sell |
3,900
-1,700
| -30% | -$398K | ﹤0.01% | 1250 |
|
|
2023
Q4 | $1.45M | Buy |
5,600
+2,600
| +87% | +$639K | ﹤0.01% | 908 |
|
|
2023
Q3 | $771K | Buy |
3,000
+700
| +30% | +$187K | ﹤0.01% | 1087 |
|
|
2023
Q2 | $655K | Buy |
2,300
+200
| +10% | +$59.5K | ﹤0.01% | 1037 |
|
|
2023
Q1 | $584K | Sell |
2,100
-4,000
| -66% | -$1.11M | ﹤0.01% | 958 |
|
|
2022
Q4 | $1.69M | Buy |
6,100
+100
| +2% | +$28.2K | 0.01% | 761 |
|
|
2022
Q3 | $1.6M | Buy |
6,000
+200
| +3% | +$42.5K | 0.01% | 847 |
|
|
2022
Q2 | $1.18M | Sell |
5,800
-4,800
| -45% | -$981K | 0.01% | 955 |
|
|
2022
Q1 | $2.23M | Sell |
10,600
-6,600
| -38% | -$1.44M | 0.01% | 1005 |
|
|
2021
Q4 | $4.13M | Sell |
17,200
-2,000
| -10% | -$514K | 0.01% | 885 |
|
|
2021
Q3 | $5.43M | Buy |
19,200
+9,400
| +96% | +$3.08M | 0.01% | 830 |
|
|
2021
Q2 | $3.39M | Buy |
9,800
+3,200
| +48% | +$969K | 0.01% | 841 |
|
|
2021
Q1 | $1.85M | Buy |
6,600
+400
| +6% | +$108K | 0.01% | 961 |
|
|
2020
Q4 | $1.52M | Sell |
6,200
-10,200
| -62% | -$2.63M | 0.01% | 954 |
|
|
2020
Q3 | $4.65M | Buy |
16,400
+2,100
| +15% | +$586K | 0.02% | 533 |
|
|
2020
Q2 | $3.83M | Buy |
14,300
+8,700
| +155% | +$2.62M | 0.03% | 511 |
|
|
2020
Q1 | $1.77M | Sell |
5,600
-28,700
| -84% | -$8.71M | 0.03% | 554 |
|
|
2019
Q4 | $10.2M | Buy |
34,300
+8,000
| +30% | +$2.22M | 0.05% | 357 |
|
|
2019
Q3 | $6.12M | Sell |
26,300
-5,900
| -18% | -$1.37M | 0.04% | 390 |
|
|
2019
Q2 | $7.53M | Buy |
32,200
+24,500
| +318% | +$5.66M | 0.05% | 360 |
|
|
2019
Q1 | $1.82M | Buy |
7,700
+2,200
| +40% | +$693K | 0.02% | 638 |
|
|
2018
Q4 | $1.66M | Buy |
5,500
+1,500
| +38% | +$479K | 0.02% | 488 |
|
|
2018
Q3 | $1.41M | Buy |
4,000
+3,200
| +400% | +$1.1M | 0.02% | 510 |
|
|
2018
Q2 | $232K | Buy |
+800
| New | +$225K | ﹤0.01% | 563 |
|
|
2017
Q1 | – | Sell |
-1,500
| Closed | -$425K | – | 880 |
|
|
2016
Q4 | $425K | Buy |
+1,500
| New | +$445K | 0.01% | 621 |
|
|
2013
Q3 | – | Sell |
-8,900
| Closed | -$1.92M | – | 509 |
|
|
2013
Q2 | $1.92M | Buy |
+8,900
| New | +$1.9M | 0.02% | 262 |
|
Other funds holding BIIB
VCM
VPM
Capstone Investment Advisors's BIIB Position: Q1 2026 in Review
Capstone Investment Advisors sold out of Biogen (BIIB) in Q1 2026, closing a stake of 2,445 shares — an estimated $451K sold.
Capstone Investment Advisors first reported a position in BIIB in Q3 2013 and held it in 33 quarters. The position peaked at $7.01M in Q1 2019. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Capstone Investment Advisors reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- Capstone Investment Advisors sold 2,445 Biogen shares in Q1 2026, an estimated $451K.
- Capstone Investment Advisors first reported a position in Biogen in Q3 2013 and held it in 33 quarters.
- Capstone Investment Advisors's Biogen position peaked at $7.01M in Q1 2019.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.